Low-dose vaginal E2 tablets effectively treat atrophic vaginitis
Twelve weeks of vaginal tablets with either 25 µg or 10 µg estradiol (E2) relieves vaginal symptoms, improves urogenital atrophy, decreases vaginal pH, and increases maturation of the vaginal and urethral epithelium in women with atrophic vaginitis, according to the findings of a multicenter, randomized, double-blind, placebo-controlled trial.
Twelve weeks of vaginal tablets with either 25 µg or 10 µg estradiol (E2) relieves vaginal symptoms, improves urogenital atrophy, decreases vaginal pH, and increases maturation of the vaginal and urethral epithelium in women with atrophic vaginitis, according to the findings of a multicenter, randomized, double-blind, placebo-controlled trial.
The study included 230 postmenopausal women. While improvements were greater with 25 µg than with 10 µg, both doses were effective; efficacy, at least with the 25 µg dose, was maintained to week 52.
Bachmann G, Lobo RA, Gut R, et al. Efficacy of low-dose estradiol vaginal tablets in the treatment of atrophic vaginitis: a randomized controlled trial. Obstet Gynecol. 2008;111:67-76.
Newsletter
Get the latest clinical updates, case studies, and expert commentary in obstetric and gynecologic care. Sign up now to stay informed.
Trimethoprim–sulfamethoxazole not found to increase infant birth weight in HIV cases
July 9th 2025A recent randomized trial found no significant improvement in birth weight or key birth outcomes from antenatal trimethoprim–sulfamethoxazole prophylaxis in human immunodeficiency virus-positive pregnant women.
Read More
